Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025



[
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025
[og_img]
https://www.investing.com/news/press-releases/nuvalent-to-present-new-preclinical-data-on-alkselective-inhibitor-neladalkib-and-ros1selective-inhibitor-zidesamtinib-at-aacr-annual-meeting-2025-93CH-3948134


Investing.com

Latest articles

spot_imgspot_img

Related articles

spot_imgspot_img